Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods
Ching‐Yu Wang(National Taiwan University), Almut G. Winterstein(University of Florida), Jesse A. Berlin(Janssen (Belgium)), Nancy C. Santanello(United States Military Academy), Jie Li(United States Food and Drug Administration), Wei Zhou(Broad Institute), Kourtney J. Davis(Research Triangle Park Foundation), John D. Seeger(New England College of Optometry), Barry J. Gertz(Blackstone (United States)), Nancy A Dreyer(IQVIA (United Kingdom))
Cited by 12
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
The association between hepatitis C infection and survival after orthotopic liver transplantation
|Gastroenterology|2002|1k
The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis
|Clinical Infectious Diseases|2005|788